Tyra Biosciences, Inc. (NASDAQ:TYRA) Director Gilla Kaplan Sells 6,814 Shares

Tyra Biosciences, Inc. (NASDAQ:TYRA - Get Free Report) Director Gilla Kaplan sold 6,814 shares of the business's stock in a transaction dated Monday, June 16th. The stock was sold at an average price of $10.38, for a total transaction of $70,729.32. Following the completion of the sale, the director now owns 37,809 shares in the company, valued at approximately $392,457.42. This trade represents a 15.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Gilla Kaplan also recently made the following trade(s):

• On Friday, June 13th, Gilla Kaplan sold 15,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total value of $154,650.00.
• On Thursday, June 12th, Gilla Kaplan sold 30,000 shares of Tyra Biosciences stock. The stock was sold at an average price of $10.31, for a total value of $309,300.00.

Tyra Biosciences Price Performance

Shares of TYRA traded down $0.21 during mid-day trading on Monday, reaching $10.22. 324,671 shares of the company's stock traded hands, compared to its average volume of 279,048. The stock's 50-day moving average is $9.63 and its two-hundred day moving average is $11.89. Tyra Biosciences, Inc. has a 12 month low of $6.42 and a 12 month high of $29.60. The stock has a market cap of $542.58 million, a P/E ratio of -6.35 and a beta of 1.07.

Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.47) EPS for the quarter, beating the consensus estimate of ($0.49) by $0.02. Research analysts predict that Tyra Biosciences, Inc. will post -1.57 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in TYRA. Rhumbline Advisers lifted its holdings in Tyra Biosciences by 7.2% during the 1st quarter. Rhumbline Advisers now owns 28,081 shares of the company's stock valued at $261,000 after buying an additional 1,879 shares in the last quarter. Jane Street Group LLC bought a new position in Tyra Biosciences in the 1st quarter worth about $324,000. Woodline Partners LP purchased a new position in shares of Tyra Biosciences during the first quarter worth approximately $931,000. Goldman Sachs Group Inc. boosted its holdings in shares of Tyra Biosciences by 21.7% in the first quarter. Goldman Sachs Group Inc. now owns 78,006 shares of the company's stock valued at $725,000 after purchasing an additional 13,896 shares during the period. Finally, Polar Asset Management Partners Inc. boosted its holdings in shares of Tyra Biosciences by 27.1% in the first quarter. Polar Asset Management Partners Inc. now owns 141,241 shares of the company's stock valued at $1,314,000 after purchasing an additional 30,134 shares during the period. 84.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TYRA has been the subject of several analyst reports. HC Wainwright reiterated a "buy" rating and issued a $30.00 target price on shares of Tyra Biosciences in a report on Monday, March 31st. Wedbush restated an "outperform" rating and issued a $30.00 price target on shares of Tyra Biosciences in a research report on Friday, March 28th. Finally, Piper Sandler assumed coverage on shares of Tyra Biosciences in a research report on Wednesday, May 21st. They set an "overweight" rating and a $33.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $30.83.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.